Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Infectious diseases 14

Infectious Diseases

recent-pharma-happenings-for-nestle-gsk-astrazeneca

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Nestle to acquire Aimmune Therapeutics; Vir Bio & GSK’s COVID-19 monoclonal antibody therapy; AstraZeneca’s Farxiga scores goal in Phase III CDK trial

Nestle acquires peanut allergy treatment with USD 2 Billion Aimmune buyout Nestle has announced a definitive agreement to extend its acquisition of Aimmune Therapeutics. Nestle will pay an additional amount of USD 2 Billion to buy the remaining shares of Aimmune. With the acquisition, Nestle will gain Aimmune's Palforzia, expanding its broader spectrum of solutions for children living with food allergies. Palforzia is the first therapy approved to reduce the frequency and severity of allergic reactions associated with Peanut allergy, including anaphylaxis, in children aged 4 through 17. The drug can be used in conjunction with a peanut-avoidant diet....

Explore More...

Business Cocktail

Antibiotic Resistance: The Big Challenge of Healthcare Industry

Hepatitis C drugs re-energize global fight over patents

Vulvovaginal Candidiasis

Cytomegalovirus infection Market

Science Events of the Year

CDC study reveals; Jevtana receives yes; Herantis secures; Immuno-oncology is not cost-effective

Aurobindo’s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika

Merck’s Antibody for Clostridium Difficile

Biosimilar Market in India

Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV

dengvaxia

Dengvaxia: Boon for Dengue

Sun Pharma & ICGEB announce collaboration; Boehringer Ingelheim and Lupin Sign deal; Daiichi Sankyo Announces; Catalent Pharma Solutions partners with Samsung Bioepis; Celltrion Healthcare and Teva enters into exclusive business collaboration agreement

FDA Approves STELARA; Novartis announces AMG 334; AbbVie’s HCV Regimen; PaizaBio Gains CFDA Approval; WuXi Biologics completes construction

FDA grants approval; Sanaria receives fast-track designation; Sanofi and Regeneron’s next blockbuster; Allele receives NIH grant

Sygnis AG and ECACC Collaboration; BioNTech and Genentech Partnership; Partnership between Zydus Cadila and Takeda; Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly